164 related articles for article (PubMed ID: 24890549)
21. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
23. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
24. Oral cancer-associated paraneoplastic syndromes.
Feller L; Wood NH; Khammissa RA; Chikte UM; Essop R; Meyerov R; Lemmer J
SADJ; 2010 Oct; 65(9):424-6. PubMed ID: 21180290
[TBL] [Abstract][Full Text] [Related]
25. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET).
Symington M; Davies L; Kaltsas G; Weickert MO
BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28331027
[TBL] [Abstract][Full Text] [Related]
26. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.
Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Guarnotta V; Ragni A; Zanata I; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():665698. PubMed ID: 34093441
[TBL] [Abstract][Full Text] [Related]
27. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
28. Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy.
Onuma E; Sato K; Saito H; Tsunenari T; Ishii K; Esaki K; Yabuta N; Wakahara Y; Yamada-Okabe H; Ogata E
Anticancer Res; 2004; 24(5A):2665-73. PubMed ID: 15517871
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic neuroendocrine tumor associated with humoral hypercalcemia of malignancy and carcinoid tumor: a case report and review of the literature.
Shah RH; Martinez D
Pancreas; 2013 Apr; 42(3):549-51. PubMed ID: 23211368
[No Abstract] [Full Text] [Related]
30. Pancreatic neuroendocrine tumor with extensive vascularisation and parathyroid hormone-related protein (PTHrP)--associated hypercalcemia of malignancy.
Clemens P; Gregor M; Lamberts R
Exp Clin Endocrinol Diabetes; 2001; 109(7):378-85. PubMed ID: 11573150
[TBL] [Abstract][Full Text] [Related]
31. Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
Behdadnia A; Jeddi M
J Med Case Rep; 2023 Sep; 17(1):400. PubMed ID: 37670372
[TBL] [Abstract][Full Text] [Related]
32. Expression of parathyroid hormone-related protein mRNA in tumors obtained from patients with humoral hypercalcemia of malignancy.
Honda S; Yamaguchi K; Suzuki M; Sato Y; Adachi I; Kimura S; Abe K
Jpn J Cancer Res; 1988 Jun; 79(6):677-81. PubMed ID: 3137193
[TBL] [Abstract][Full Text] [Related]
33. Is denosumab a long-term option for the treatment of parathyroid carcinoma?
Baretić M
QJM; 2016 Apr; 109(4):288. PubMed ID: 26803154
[No Abstract] [Full Text] [Related]
34. Case report: lanreotide in the management of hypercalcemia of malignancy.
Anthony LB; May ME; Oates JA
Am J Med Sci; 1995 Jun; 309(6):312-4. PubMed ID: 7771500
[TBL] [Abstract][Full Text] [Related]
35. Response to "Is denosumab a long-term option for the treatment of parathyroid carcinoma?".
Tong CV; Hussein Z
QJM; 2016 Apr; 109(4):289. PubMed ID: 26803152
[No Abstract] [Full Text] [Related]
36. The humoral hypercalcemia of benignancy. A newly appreciated syndrome.
Knecht TP; Behling CA; Burton DW; Glass CK; Deftos LJ
Am J Clin Pathol; 1996 Apr; 105(4):487-92. PubMed ID: 8604692
[TBL] [Abstract][Full Text] [Related]
37. Rare case of pancreatic neuroendocrine tumour presenting as paraneoplastic hypercalcaemia.
Ferrel B; Franko J; Tee MC
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33858893
[TBL] [Abstract][Full Text] [Related]
38. Malignant hypercalcemia in vulvar cancer.
Bilenchi R; Poggiali S; Pisani C; Santopietro R; Miracco C; Vatti R; Lucani B; Andreassi A; Gonnelli S
Minerva Ginecol; 2005 Oct; 57(5):569-74. PubMed ID: 16205603
[TBL] [Abstract][Full Text] [Related]
39. Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia.
Li Y; Fan CY; Manni A; Simonds WF
BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32350052
[TBL] [Abstract][Full Text] [Related]
40. Hypercalcemia as the first finding of late recurrence of a PTHrP neuroendocrine tumor of the pancreas.
Febrero B; Gómez B; Ruiz-Manzanera JJ; Ros-Madrid I; Rodríguez JM
Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):31-32. PubMed ID: 38350837
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
